Literature DB >> 22865632

Epigenetic inactivation of endothelin-2 and endothelin-3 in colon cancer.

Rong Wang1, Christiane V Löhr, Kay Fischer, W Mohaiza Dashwood, Jeffrey A Greenwood, Emily Ho, David E Williams, Hassan Ashktorab, Michael R Dashwood, Roderick H Dashwood.   

Abstract

Endothelin-1 (ET-1) and its receptors are overexpressed in human cancers, but much less is known about the roles of ET-2 and ET-3 in cancer etiology. We sought to examine human and rat colon tumors for dysregulation of ET-2 and ET-3 expression and determine the underlying mechanisms. Human primary colon cancers and carcinogen-induced rat colon tumors were subjected to real-time RT-PCR, immunoblotting and immunohistochemistry; EDN2 and EDN3 genes were examined by methylation-specific PCR, bisulfite sequencing and pyrosequencing; and forced expression of ET-2 and ET-3 was conducted in human colon cancer cells followed by real-time cell migration and invasion assays. Rat and human colon tumors had markedly reduced expression of ET-2 and ET-3 mRNA and protein compared with matched controls. Mechanistic studies revealed hypermethylation of EDN2 and EDN3 genes in human primary colon cancers and in a panel of human colon cancer cell lines. Forced expression of ET-2 and ET-3 attenuated significantly the migration and invasion of human colon cancer cells. We conclude that epigenetic inactivation of ET-2 and ET-3 occurs frequently in both rat and human colon cancers. Current therapeutic strategies target overexpressed members of the ET axis via small molecule inhibitors and receptor antagonists, but this work supports a complementary approach based on the re-expression of ET-2 and ET-3 as natural antagonists of ET-1 in colon cancer.
Copyright © 2012 UICC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22865632      PMCID: PMC3500448          DOI: 10.1002/ijc.27762

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  17 in total

Review 1.  The importance of endothelin axis in initiation, progression, and therapy of ovarian cancer.

Authors:  Laura Rosanò; Francesca Spinella; Anna Bagnato
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-06-10       Impact factor: 3.619

Review 2.  Endothelin--role in vascular disease.

Authors:  D Abraham; M Dashwood
Journal:  Rheumatology (Oxford)       Date:  2008-10       Impact factor: 7.580

3.  The endothelin receptor B (EDNRB) promoter displays heterogeneous, site specific methylation patterns in normal and tumor cells.

Authors:  M M Pao; M Tsutsumi; G Liang; E Uzvolgyi; F A Gonzales; P A Jones
Journal:  Hum Mol Genet       Date:  2001-04-15       Impact factor: 6.150

Review 4.  Endothelin-2, the forgotten isoform: emerging role in the cardiovascular system, ovarian development, immunology and cancer.

Authors:  Lowell Ling; Janet J Maguire; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

Review 5.  Endothelins in breast tumour cell invasion.

Authors:  Matthew J Grimshaw
Journal:  Cancer Lett       Date:  2005-05-26       Impact factor: 8.679

6.  A role for endothelin-2 and its receptors in breast tumor cell invasion.

Authors:  Matthew J Grimshaw; Thorsten Hagemann; Ayse Ayhan; Cheryl E Gillett; Claudia Binder; Frances R Balkwill
Journal:  Cancer Res       Date:  2004-04-01       Impact factor: 12.701

7.  Endothelin-2 is a hypoxia-induced autocrine survival factor for breast tumor cells.

Authors:  Matthew J Grimshaw; Stuart Naylor; Frances R Balkwill
Journal:  Mol Cancer Ther       Date:  2002-12       Impact factor: 6.261

8.  Endothelin-3 growth factor levels decreased in cervical cancer compared with normal cervical epithelial cells.

Authors:  De Jun Sun; Ying Liu; Dong Cheng Lu; Woonbong Kim; Je Ho Lee; Jonathan Maynard; Albert Deisseroth
Journal:  Hum Pathol       Date:  2007-04-18       Impact factor: 3.466

Review 9.  Endothelin receptor antagonism and cancer.

Authors:  A Bhalla; S Haque; I Taylor; M Winslet; M Loizidou
Journal:  Eur J Clin Invest       Date:  2009-06       Impact factor: 4.686

10.  Frequent loss of endothelin-3 (EDN3) expression due to epigenetic inactivation in human breast cancer.

Authors:  Frank Wiesmann; Jürgen Veeck; Oliver Galm; Arndt Hartmann; Manel Esteller; Ruth Knüchel; Edgar Dahl
Journal:  Breast Cancer Res       Date:  2009-06-15       Impact factor: 6.466

View more
  19 in total

1.  Divergent roles of p120-catenin isoforms linked to altered cell viability, proliferation, and invasiveness in carcinogen-induced rat skin tumors.

Authors:  Rong Wang; Ying-Shiuan Chen; Wan-Mohaiza Dashwood; Qingjie Li; Christiane V Löhr; Kay Fischer; Emily Ho; David E Williams; Roderick H Dashwood
Journal:  Mol Carcinog       Date:  2017-03-06       Impact factor: 4.784

Review 2.  Endothelin 1 in cancer: biological implications and therapeutic opportunities.

Authors:  Laura Rosanò; Francesca Spinella; Anna Bagnato
Journal:  Nat Rev Cancer       Date:  2013-07-25       Impact factor: 60.716

3.  Reciprocal regulation of BMF and BIRC5 (Survivin) linked to Eomes overexpression in colorectal cancer.

Authors:  Rong Wang; Yuki Kang; Christiane V Löhr; Kay A Fischer; C Samuel Bradford; Gavin Johnson; Wan Mohaiza Dashwood; David E Williams; Emily Ho; Roderick H Dashwood
Journal:  Cancer Lett       Date:  2016-08-15       Impact factor: 8.679

4.  Epigenetic silencing of endothelin-3 in colorectal cancer.

Authors:  J Olender; E Nowakowska-Zajdel; C Kruszniewska-Rajs; J Orchel; U Mazurek; A Wierzgoń; T Kokot; M Muc-Wierzgoń
Journal:  Int J Immunopathol Pharmacol       Date:  2015-12-18       Impact factor: 3.219

5.  Generation and characterization of an endothelin-2 iCre mouse.

Authors:  Joseph A Cacioppo; Yongbum Koo; Po-Ching Patrick Lin; Arnon Gal; CheMyong Ko
Journal:  Genesis       Date:  2015-02-12       Impact factor: 2.487

6.  Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.

Authors:  Hailing Yang; Weiqun Mao; Cristian Rodriguez-Aguayo; Lingegowda S Mangala; Geoffrey Bartholomeusz; Lakesla R Iles; Nicholas B Jennings; Ahmed Ashour Ahmed; Anil K Sood; Gabriel Lopez-Berestein; Zhen Lu; Robert C Bast
Journal:  Clin Cancer Res       Date:  2018-07-03       Impact factor: 12.531

7.  Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP).

Authors:  Ahmet M Ulusan; Praveen Rajendran; Wan Mohaiza Dashwood; Omer F Yavuz; Sabeeta Kapoor; Trace A Gustafson; Michelle I Savage; Powel H Brown; Shizuko Sei; Altaf Mohammed; Eduardo Vilar; Roderick H Dashwood
Journal:  Cancer Prev Res (Phila)       Date:  2020-12-04

Review 8.  Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12.

Authors:  J J Maguire; A P Davenport
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

Review 9.  Endothelin.

Authors:  Anthony P Davenport; Kelly A Hyndman; Neeraj Dhaun; Christopher Southan; Donald E Kohan; Jennifer S Pollock; David M Pollock; David J Webb; Janet J Maguire
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

10.  A role for low-abundance miRNAs in colon cancer: the miR-206/Krüppel-like factor 4 (KLF4) axis.

Authors:  Mansi A Parasramka; W Mohaiza Dashwood; Rong Wang; Hassaan H Saeed; David E Williams; Emily Ho; Roderick H Dashwood
Journal:  Clin Epigenetics       Date:  2012-09-24       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.